CN1516584A - 螺吡唑化合物 - Google Patents

螺吡唑化合物 Download PDF

Info

Publication number
CN1516584A
CN1516584A CNA028121767A CN02812176A CN1516584A CN 1516584 A CN1516584 A CN 1516584A CN A028121767 A CNA028121767 A CN A028121767A CN 02812176 A CN02812176 A CN 02812176A CN 1516584 A CN1516584 A CN 1516584A
Authority
CN
China
Prior art keywords
alkyl
phenyl
compound
cycloalkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028121767A
Other languages
English (en)
Chinese (zh)
Inventor
R��R����ϣ��
R·R·格希林
D·开尔
G·李
P·哈拉格兹罗
S·维克多里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CN1516584A publication Critical patent/CN1516584A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA028121767A 2001-04-18 2002-04-18 螺吡唑化合物 Pending CN1516584A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28467501P 2001-04-18 2001-04-18
US60/284,675 2001-04-18

Publications (1)

Publication Number Publication Date
CN1516584A true CN1516584A (zh) 2004-07-28

Family

ID=23091099

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028121767A Pending CN1516584A (zh) 2001-04-18 2002-04-18 螺吡唑化合物

Country Status (27)

Country Link
US (2) US6635653B2 (cg-RX-API-DMAC7.html)
EP (1) EP1385515B1 (cg-RX-API-DMAC7.html)
JP (1) JP4342181B2 (cg-RX-API-DMAC7.html)
KR (1) KR100628292B1 (cg-RX-API-DMAC7.html)
CN (1) CN1516584A (cg-RX-API-DMAC7.html)
AT (1) ATE403429T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002311833B2 (cg-RX-API-DMAC7.html)
BR (1) BR0209127A (cg-RX-API-DMAC7.html)
CA (1) CA2444634C (cg-RX-API-DMAC7.html)
CY (1) CY1108454T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032849A3 (cg-RX-API-DMAC7.html)
DE (1) DE60228071D1 (cg-RX-API-DMAC7.html)
DK (1) DK1385515T3 (cg-RX-API-DMAC7.html)
ES (1) ES2312584T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0401333A3 (cg-RX-API-DMAC7.html)
IL (2) IL158485A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03009604A (cg-RX-API-DMAC7.html)
NO (1) NO20034660L (cg-RX-API-DMAC7.html)
NZ (1) NZ528978A (cg-RX-API-DMAC7.html)
PL (1) PL367263A1 (cg-RX-API-DMAC7.html)
PT (1) PT1385515E (cg-RX-API-DMAC7.html)
RU (1) RU2299883C2 (cg-RX-API-DMAC7.html)
SI (1) SI1385515T1 (cg-RX-API-DMAC7.html)
UA (1) UA74439C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002085355A1 (cg-RX-API-DMAC7.html)
YU (1) YU82403A (cg-RX-API-DMAC7.html)
ZA (1) ZA200308103B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825681A (zh) * 2020-07-07 2020-10-27 扬州大学 一种合成(e)-亚苄基螺吡唑吡咯嗪酮类化合物的方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1516584A (zh) * 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2004034983A2 (en) * 2002-10-17 2004-04-29 Euro-Celtique, S.A. Preparation of triazospiro compounds
US20040242583A1 (en) * 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
WO2004103305A2 (en) * 2003-05-16 2004-12-02 Euroceltique S.A. Spiropyrazole compound
WO2005011665A1 (en) * 2003-07-22 2005-02-10 Arakis Ltd. The use of proglumide for the treatment of emesis
CN1984663A (zh) 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
NZ556628A (en) 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CN103202840B (zh) 2006-11-28 2015-02-11 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
EP2397477B1 (en) 2007-01-16 2014-03-05 Purdue Pharma LP Heterocyclic-substituted piperidine compounds and the uses thereof
EP2150552B1 (en) 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
WO2009027820A2 (en) 2007-08-31 2009-03-05 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
RS52590B2 (sr) 2008-07-21 2018-05-31 Purdue Pharma Lp Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
JP5872585B2 (ja) 2010-12-22 2016-03-01 パーデュー、ファーマ、リミテッド、パートナーシップ リン置換キノキサリンタイプピペリジン化合物とその使用
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB157497A (cg-RX-API-DMAC7.html) *
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3325499A (en) 1964-11-02 1967-06-13 Mcneilab Inc 1-(1-hydrocarbyl-4-piperdyl)-2-indolinone
US3923993A (en) * 1973-06-28 1975-12-02 American Home Prod Process for treating neuroendocrinopathic diseases employing fluspirilene
DE2609645A1 (de) 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US4410528A (en) 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
JPS58180481A (ja) 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
AU688498B2 (en) 1994-04-14 1998-03-12 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
FR2722190B1 (fr) 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US6150355A (en) 1995-09-13 2000-11-21 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidine derivative
DE69736776T2 (de) 1996-04-19 2007-01-18 Neurosearch A/S 1-(4-piperidyl)-benzimidazole mit neurotropher aktivität
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
CA2291094C (en) 1997-05-30 2008-02-26 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivative
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
SI0921125T1 (en) 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
PL342046A1 (en) 1998-01-19 2001-05-21 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidine compounds as agonists of orl1 receptor
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
JP2002515503A (ja) * 1998-05-18 2002-05-28 ノボ ノルディスク アクティーゼルスカブ オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
JP2004531456A (ja) 2000-09-06 2004-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾールを用いてアレルギーを治療する方法
CN1516584A (zh) * 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825681A (zh) * 2020-07-07 2020-10-27 扬州大学 一种合成(e)-亚苄基螺吡唑吡咯嗪酮类化合物的方法

Also Published As

Publication number Publication date
WO2002085355A1 (en) 2002-10-31
PL367263A1 (en) 2005-02-21
US20030027834A1 (en) 2003-02-06
JP2004531531A (ja) 2004-10-14
AU2002311833B2 (en) 2005-04-28
US20040087641A1 (en) 2004-05-06
NO20034660L (no) 2003-12-17
CZ20032849A3 (en) 2004-03-17
NO20034660D0 (no) 2003-10-17
NZ528978A (en) 2004-06-25
EP1385515A4 (en) 2004-06-30
HK1062885A1 (en) 2004-12-03
JP4342181B2 (ja) 2009-10-14
YU82403A (sh) 2006-08-17
MXPA03009604A (es) 2004-04-02
RU2003133455A (ru) 2005-05-10
DK1385515T3 (da) 2008-10-27
SI1385515T1 (sl) 2008-12-31
CY1108454T1 (el) 2014-04-09
HUP0401333A3 (en) 2004-11-29
ES2312584T3 (es) 2009-03-01
ZA200308103B (en) 2004-10-18
CA2444634C (en) 2011-06-07
DE60228071D1 (de) 2008-09-18
IL158485A0 (en) 2004-05-12
PT1385515E (pt) 2008-09-15
RU2299883C2 (ru) 2007-05-27
ATE403429T1 (de) 2008-08-15
EP1385515A1 (en) 2004-02-04
UA74439C2 (uk) 2005-12-15
IL158485A (en) 2009-09-01
KR100628292B1 (ko) 2006-09-27
HUP0401333A2 (hu) 2004-10-28
US6635653B2 (en) 2003-10-21
BR0209127A (pt) 2006-03-21
CA2444634A1 (en) 2002-10-31
KR20040008159A (ko) 2004-01-28
EP1385515B1 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
CN100352816C (zh) 伤害感受肽类似物
JP4489354B2 (ja) スピロインデンおよびスピロインダン化合物類
JP4342181B2 (ja) スピロピラゾール化合物
JP4401076B2 (ja) ベンズイミダゾロン化合物
US20090253727A1 (en) Nociceptin analogs
RU2265018C2 (ru) Производные бензимидазола и фармацевтические композиции на их основе
HK1070573B (en) Nociceptin compounds
HK1127032A (en) Quinolinone derivatives and their use to treat pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20040728